High SOX4 expression has been associated with better prognosis for patients with hepatocelluar carcinoma, medulloblastoma, and bladder cancer [5, 13, 14], but with shorter survival in prostate cancer, gastric cancer, and colon cancer [7, 9, 10]. Here, SOX4 is linked to prostate cancer.